Ann: Monthly Activities/Appendix 4C Cash Flow Report, page-61

I’m also a little disappointed with cash receipts. Thought it would increased slightly but I have to remind myself it’s a growth company with some setbacks due to covid pandemic and this has delayed initiatives and strategies imo.

I did like the bit on ANMA. At the end of April 2021, upgrade has resulted in the factory now having the capacity to manufacture in excess of 1 million cans per month.

This bit is also good.”JAT continued with its strategy of:
1. Establishing its China-located business;
2. Developing its own proprietary products;
3. Expanding and improving its ANMA manufacturing facility;
4. Reducing risk by manufacturing products outside Australia; and
5. Expand sales destinations so as not to be wholly reliant on the China market”.

Best part is;
JAT expect a significant increase in revenue for the 2022 year. The directors basing their views due to previous strategies taking effects and also the following.

- strong order book is building at the ANMA factory as well as enquiries from potential new customers.
- Plans are underway to acquire new equipment to meet the demand and for the production of new products.
- The opening of JAT’s Shanghai retail store has been delayed for almost two years due to lock downs in Shanghai and delays in regulatory approvals. The regulators have issued new documents and it is expected that, subject to any other unforeseen circumstances, the store should open in the September quarter.
-JAT has placed the first order for Babycare products (see announcement dated 19 July 2021). It is expected the first products will be distributed to Australian customers in August 2021.
- New products developed by JAT have been welcomed by both local pharmacy chains and overseas distributors.
- The Company is confident the sale of those products will generate significant revenue.

As always DYOR